Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans

Science Translational Medicine

Volumn 5, Issue 185, 2013, Pages

  Kim, Mi Kyung ^a,b   Breitbach, Caroline J ^c   Moon, Anne ^c   Heo, Jeong ^a   Lee, Yu Kyoung ^b   Cho, Mong ^a   Lee, Jun Woo ^a   Kim, Seong Geun ^a   Kang, Dae Hwan ^a   Bell, John C ^c,d   Park, Byeong Ho ^e   Kirn, David H ^c   Hwang, Tae Ho ^a,b  

^a Pusan National University   (South Korea)

^b SillaJen Inc   (South Korea)

^c Jennerex Inc   (United States)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; TUMOR ANTIGEN;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CLEAR CELL CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DISEASE MODEL; DRUG CYTOTOXICITY; DRUG TARGETING; GENE REARRANGEMENT; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LIVER CANCER; LIVER METASTASIS; LUNG SMALL CELL CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR NECROSIS; VACCINIA VIRUS;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; NECROSIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RABBITS; SERUM; SURVIVAL ANALYSIS; VACCINIA VIRUS;

EID: 84878279239     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005361     Document Type: Article

References (72)

1. P. Sharma, K. Wagner, J. D. Wolchok, J. P. Allison, Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer 11, 805-812 (2011).
2. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
3. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J. F. Baurain, A. Testori, J. J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. H. Miller Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T. T. Chen, R. Humphrey, A. Hoos, J. D. Wolchok, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
4. C. S. Higano, P. F. Schellhammer, E. J. Small, P. A. Burch, J. Nemunaitis, L. Yuh, N. Provost, M. W. Frohlich, Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
5. D. Kerr, Clinical development of gene therapy for colorectal cancer. Nat. Rev. Cancer 3, 615-622 (2003).
6. A. G. Zeimet, C. Marth, Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415-422 (2003).
7. F. McCormick, Cancer gene therapy: Fringe or cutting edge? Nat. Rev. Cancer 1, 130-141 (2001).
8. S. A. Rosenberg, J. C. Yang, N. P. Restifo, Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
9. R. J. Amato, N. Drury, S. Naylor, J. Jac, S. Saxena, A. Cao, J. Hernandez-McClain, R. Harrop, Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial. J. Immunother. 31, 577-585 (2008).
10. J. L. Gulley, P. M. Arlen, K. Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, J. P. Higgins, J. W. Hodge, S. M. Steinberg, H. Kotz, W. L. Dahut, J. Schlom, Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14, 3060-3069 (2008).
11. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, D. H. Kirn, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645 (1997).
12. J. C. Bell, B. Lichty, D. Stojdl, Getting oncolytic virus therapies off the ground. Cancer Cell 4, 7-11 (2003).
13. S. H. Thorne, T. Hermiston, D. Kirn, Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol. 32, 537-548 (2005).
14. T. C. Liu, E. Galanis, D. Kirn, Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117 (2007).
15. D. Kirn, R. L. Martuza, J. Zwiebel, Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787 (2001).
16. M. C. Coffey, J. E. Strong, P. A. Forsyth, P. W. Lee, Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334 (1998).
17. D. F. Stojdl, B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, J. C. Bell, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825 (2000).
18. D. F. Stojdl, B. D. Lichty, B. R. tenOever, J. M. Paterson, A. T. Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, H. Atkins, E. G. Brown, R. K. Durbin, J. E. Durbin, J. Hiscott, J. C. Bell, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell 4, 263-275 (2003).
19. J. R. Bischoff, D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, F. McCormick, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996).
20. C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, D. Kirn, An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat. Med. 6, 1134-1139 (2000).
21. T. Mineta, S. D. Rabkin, T. Yazaki, W. D. Hunter, R. L. Martuza, Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943 (1995).
22. T. Mineta, S. D. Rabkin, R. L. Martuza, Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966 (1994).
23. T. C. Liu, T. H. Hwang, J. C. Bell, D. H. Kirn, Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: A high-value iterative loop. Mol. Ther. 16, 1006-1008 (2008).
24. T. C. Liu, D. Kirn, Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res. 67, 429-432 (2007).
25. H. L. Kaufman, D. W. Kim, G. DeRaffele, J. Mitcham, R. S. Coffin, S. Kim-Schulze, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718-730 (2010).
26. J. H. Kim, J. Y. Oh, B. H. Park, D. E. Lee, J. S. Kim, H. E. Park, M. S. Roh, J. E. Je, J. H. Yoon, S. H. Thorne, D. Kirn, T. H. Hwang, Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361-370 (2006).
27. R. J. Prestwich, E. J. Ilett, F. Errington, R. M. Diaz, L. P. Steele, T. Kottke, J. Thompson, F. Galivo, K. J. Harrington, H. S. Pandha, P. J. Selby, R. G. Vile, A. A. Melcher, Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 15, 4374-4381 (2009).
28. H. Li, A. Dutuor, X. Fu, X. Zhang, Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J. Gene Med. 9, 161-169 (2007).
29. K. A. Parato, B. D. Lichty, J. C. Bell, Diplomatic immunity: Turning a foe into an ally. Curr. Opin. Mol. Ther. 11, 13-21 (2009).
30. D. H. Kirn, Y. Wang, F. Le Boeuf, J. Bell, S. H. Thorne, Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007).
31. D. H. Kirn, S. H. Thorne, Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9, 64-71 (2009).
32. C. J. Breitbach, J. Burke, D. Jonker, J. Stephenson, A. R. Haas, L. Q. Chow, J. Nieva, T. H. Hwang, A. Moon, R. Patt, A. Pelusio, F. Le Boeuf, J. Burns, L. Evgin, N. De Silva, S. Cvancic, T. Robertson, J. E. Je, Y. S. Lee, K. Parato, J. S. Diallo, A. Fenster, M. Daneshmand, J. C. Bell, D. H. Kirn, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011).
33. D. H. Kirn, Y. Wang, W. Liang, C. H. Contag, S. H. Thorne, Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 68, 2071-2075 (2008).
34. Y. Yang, C. T. Huang, X. Huang, D. M. Pardoll, Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5, 508-515 (2004).
35. J. Zhu, J. Martinez, X. Huang, Y. Yang, Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β. Blood 109, 619-625 (2007).
36. J. Martinez, X. Huang, Y. Yang, Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc. Natl. Acad. Sci. U.S.A. 107, 6442-6447 (2010).
37. B. H. Park, T. Hwang, T. C. Liu, D. Y. Sze, J. S. Kim, H. C. Kwon, S. Y. Oh, S. Y. Han, J. H. Yoon, S. H. Hong, A. Moon, K. Speth, C. Park, Y. J. Ahn, M. Daneshmand, B. G. Rhee, H. M. Pinedo, J. C. Bell, D. H. Kirn, Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol. 9, 533-542 (2008).
38. M. J. Walport, Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066 (2001).
39. N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, J. Golay, Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171, 1581-1587 (2003).
40. A. Harjunpää, S. Junnikkala, S. Meri, Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51, 634-641 (2000).
41. J. Golay, E. Cittera, N. Di Gaetano, M. Manganini, M. Mosca, M. Nebuloni, N. van Rooijen, L. Vago, M. Introna, The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91, 176-183 (2006).
42. E. Racila, B. K. Link, W. K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, G. J. Weiner, A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 14, 6697-6703 (2008).
43. L. Bologna, E. Gotti, F. Da Roit, T. Intermesoli, A. Rambaldi, M. Introna, J. Golay, Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190, 231-239 (2013).
44. X. Ge, L. Wu, W. Hu, S. Fernandes, C. Wang, X. Li, J. R. Brown, X. Qin, rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin. Cancer Res. 17, 6702-6711 (2011).
45. W. G. Wierda, S. Padmanabhan, G. W. Chan, I. V. Gupta, S. Lisby, A. Osterborg, Hx-CD20-406 Study Investigators, Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study. Blood 118, 5126-5129 (2011).
46. S. H. Thorne, T. H. Hwang, W. E. O'Gorman, D. L. Bartlett, S. Sei, F. Kanji, C. Brown, J. Werier, J. H. Cho, D. E. Lee, Y. Wang, J. Bell, D. H. Kirn, Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350-3358 (2007).
47. F. Pascale, S. H. Ghegediban, M. Bonneau, L. Bedouet, J. Namur, V. Verret, I. Schwartz-Cornil, M. Wassef, A. Laurent, Modified model of VX2 tumor overexpressing vascular endothelial growth factor. J. Vasc. Interv. Radiol. 23, 809-817.e2 (2012).
48. K. Wang, X. Xu, Y. Nie, L. Dai, P. Wang, J. Zhang, Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma. Cancer Lett. 281, 144-150 (2009).
49. S. B. Keysar, A. Jimeno, More than markers: Biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9, 2450-2457 (2010).
50. J. M. Howard, P. Beddy, D. Ennis, M. Keogan, G. P. Pidgeon, J. V. Reynolds, Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br. J. Surg. 97, 1020-1027 (2010).
51. T. Noguchi, T. Kato, L. Wang, Y. Maeda, H. Ikeda, E. Sato, A. Knuth, S. Gnjatic, G. Ritter, S. Sakaguchi, L. J. Old, H. Shiku, H. Nishikawa, Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 72, 1672-1682 (2012).
52. C. M. Snapper, W. E. Paul, Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944-947 (1987).
53. C. M. Snapper, M. R. Kehry, B. E. Castle, J. J. Mond, Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. A redefinition of the TI-2 vs T cell-dependent antigen dichotomy. J. Immunol. 154, 1177-1187 (1995).
54. C. J. Breitbach, J. M. Paterson, C. G. Lemay, T. J. Falls, A. McGuire, K. A. Parato, D. F. Stojdl, M. Daneshmand, K. Speth, D. Kirn, J. A. McCart, H. Atkins, J. C. Bell, Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693 (2007).
55. R. D. Schreiber, L. J. Old, M. J. Smyth, Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
56. S. Radoja, T. D. Rao, D. Hillman, A. B. Frey, Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J. Immunol. 164, 2619-2628 (2000).
57. E. Georges, F. Breitburd, N. Jibard, G. Orth, Two Shope papillomavirus-associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability. J. Virol. 55, 246-250 (1985).
58. J. H. Lee, M. S. Roh, Y. K. Lee, M. K. Kim, J. Y. Han, B. H. Park, P. Trown, D. H. Kirn, T. H. Hwang, Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 17, 73-79 (2010).
59. N. K. Saxena, D. Sharma, X. Ding, S. Lin, F. Marra, D. Merlin, F. A. Anania, Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67, 2497-2507 (2007).
60. X. R. Yang, Y. Xu, B. Yu, J. Zhou, J. C. Li, S. J. Qiu, Y. H. Shi, X. Y. Wang, Z. Dai, G. M. Shi, B. Wu, L. M. Wu, G. H. Yang, B. H. Zhang, W. X. Qin, J. Fan, CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin. Cancer Res. 15, 5518-5527 (2009).
61. M. A. Nalesnik, G. Tseng, Y. Ding, G. S. Xiang, Z. L. Zheng, Y. Yu, J. W. Marsh, G. K. Michalopoulos, J. H. Luo, Gene deletions and amplifications in human hepatocellular carcinomas: Correlation with hepatocyte growth regulation. Am. J. Pathol. 180, 1495-1508 (2012).
62. G. Z. Shao, R. L. Zhou, Q. Y. Zhang, Y. Zhang, J. J. Liu, J. A. Rui, X. Wei, D. X. Ye, Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22, 5060-5069 (2003).
63. L. R. Saunders, E. Verdin, Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26, 5489-5504 (2007).
64. G. Afshar, J. P. Murnane, Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 234, 161-168 (1999).
65. I. Ferby, M. Reschke, O. Kudlacek, P. Knyazev, G. Pantè, K. Amann, W. Sommergruber, N. Kraut, A. Ullrich, R. Fässler, R. Klein, Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat. Med. 12, 568-573 (2006).
66. A. Fujimoto, Y. Totoki, T. Abe, K. A. Boroevich, F. Hosoda, H. H. Nguyen, M. Aoki, N. Hosono, M. Kubo, F. Miya, Y. Arai, H. Takahashi, T. Shirakihara, M. Nagasaki, T. Shibuya, K. Nakano, K. Watanabe-Makino, H. Tanaka, H. Nakamura, J. Kusuda, H. Ojima, K. Shimada, T. Okusaka, M. Ueno, Y. Shigekawa, Y. Kawakami, K. Arihiro, H. Ohdan, K. Gotoh, O. Ishikawa, S. Ariizumi, M. Yamamoto, T. Yamada, K. Chayama, T. Kosuge, H. Yamaue, N. Kamatani, S. Miyano, H. Nakagama, Y. Nakamura, T. Tsunoda, T. Shibata, H. Nakagawa, Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012).
67. I. Alvarez, M. Carrascal, F. Canals, L. Muixí, J. Abián, D. Jaraquemada, Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy. Proteomics Clin. Appl. 1, 286-298 (2007).
68. S. Sharma, D. J. Stumpo, A. S. Balajee, C. B. Bock, P. M. Lansdorp, R. M. Brosh Jr., P. J. Blackshear, RECQL, a member of the RecQ family of DNA helicases, suppresses chromosomal instability. Mol. Cell. Biol. 27, 1784-1794 (2007).
69. M. Lauss, A. Kriegner, K. Vierlinger, I. Visne, A. Yildiz, E. Dilaveroglu, C. Noehammer, Consensus genes of the literature to predict breast cancer recurrence. Breast Cancer Res. Treat. 110, 235-244 (2008).
70. D. F. Ma, T. Kondo, T. Nakazawa, D. F. Niu, K. Mochizuki, T. Kawasaki, T. Yamane, R. Katoh, Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum. Pathol. 41, 1550-1557 (2010).
71. D. Vimalachandran, W. Greenhalf, C. Thompson, J. Lüttges, W. Prime, F. Campbell, A. Dodson, R. Watson, T. Crnogorac-Jurcevic, N. Lemoine, J. Neoptolemos, E. Costello, High nuclear S100A6 (calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 65, 3218-3225 (2005).
72. K. Matoba, N. Iizuka, T. Gondo, T. Ishihara, H. Yamada-Okabe, T. Tamesa, N. Takemoto, K. Hashimoto, K. Sakamoto, T. Miyamoto, S. Uchimura, Y. Hamamoto, M. Oka, Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int. J. Cancer 115, 231-240 (2005).